Frequency of adverse drug reactions.

Por DeBoer, A
Publicado em 1993

A perspective on stem cell modeling of amyotrophic lateral sclerosis

Por de Boer, A Sophie, Eggan, Kevin
Publicado no Cell Cycle (2015)

Properties of Two Outward-Rectifying Channels in Root Xylem Parenchyma Cells Suggest a Role in K+ Homeostasis and Long-Distance Signaling.

Por Wegner, L. H., De Boer, A. H.
Publicado em 1997

A fusicoccin binding protein belongs to the family of 14-3-3 brain protein homologs.

Por Korthout, H A, de Boer, A H
Publicado em 1994

The Blood-Brain Barrier: Clinical Implications for Drug Delivery to the Brain

Por De Boer, A G, Breimer, D D
Publicado no J R Coll Physicians Lond (1994)

Genetic Mutations Occur Gradually in In Vivo Populations of Mycobacterium tuberculosis Bacteria

Por de Boer, A. S., van Soolingen, D., Borgdorff, M. W.
Publicado em 2001

Plasma level profile of nitrazepam (Mogadon®) following oral administration

Por Breimer, D. D., Bracht, H., De Boer, A. G.
Publicado em 1977

Brain Drug Targeting: The Future of Brain Drug Development.: Pardridge W M. Cambridge University Press, 2001, £65.00. ISBN 0 521 80077 3

Por Kamphorst, W, de Boer, A G, Gaillard, P J
Publicado em 2002

The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

Por De Boer, A, Stiekema, J C, Danhof, M, Breimer, D D
Publicado em 1991

Nutritional aspects of changes in disease patterns in the Western Pacific region.

Por Cavalli-Sforza, L. T., Rosman, A., de Boer, A. S., Darnton-Hill, I.
Publicado em 1996

Characterization of the replication region of the Bacillus subtilis plasmid pLS20: a novel type of replicon.

Por Meijer, W J, de Boer, A J, van Tongeren, S, Venema, G, Bron, S
Publicado em 1995

Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Por Soons, P A, De Boer, A, Cohen, A F, Breimer, D D
Publicado em 1991

The risk for breast cancer is not evidently increased in women with hyperprolactinemia

Por Dekkers, O. M., Romijn, J. A., de Boer, A., Vandenbroucke, J. P.
Publicado em 2009

Quality of life in patients with Parkinson's disease: development of a questionnaire.

Por de Boer, A G, Wijker, W, Speelman, J D, de Haes, J C
Publicado em 1996

Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.

Por Soons, P A, de Boer, A G, van Brummelen, P, Breimer, D D
Publicado em 1989

Chapter 1 Student voices on social exclusion in general primary schools

Por de Leeuw, R.R., de Boer, A.A., Minnaert, A.E.M.G.
Publicado em 2019

Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling

Por Mekhoubad, Shila, Bock, Christoph, de Boer, A. Sophie, Kiskinis, Evangelos, Meissner, Alexander, Eggan, Kevin
Publicado em 2012

pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.

Por Adema, G. J., Bakker, A. B., de Boer, A. J., Hohenstein, P., Figdor, C. G.
Publicado em 1996

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Por Bazargani, Y. T., Ugurlu, M., de Boer, A., Leufkens, H. G. M., Mantel-Teeuwisse, A. K.
Publicado no BMC Cardiovasc Disord (2018)

Purification of the Fusicoccin-Binding Protein from Oat Root Plasma Membrane by Affinity Chromatography with Biotinylated Fusicoccin.

Por Korthout, HAAJ., Van Der Hoeven, PCJ., Wagner, M. J., Van Hunnik, E., De Boer, A. H.
Publicado em 1994